Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ARVINAS, INC. (ARVN)

Arvinas swings to $169.4 million Q2 profit on VEPPANU approval and Rigel license

Positive Impact 4 of 5 earnings Written later

Arvinas reported second quarter 2026 revenue of $249.7 million, up from $22.4 million a year earlier, and net income of $169.4 million, compared with a net loss of $61.2 million in the same quarter of 2025. The results followed FDA approval of VEPPANU, the first approved PROTAC, and a license agreement with Rigel Pharmaceuticals for its global rights.

Key points

  • Q2 2026 revenue of $249.7 million included $62.5 million from the Rigel License Agreement and a $50.0 million development milestone tied to FDA approval of VEPPANU.
  • Diluted earnings per share were $2.58 for Q2 2026, compared with a loss of $0.84 per share in Q2 2025.
  • Cash, cash equivalents and marketable securities were $567.9 million as of June 30, 2026, and the company says this funds planned spending into the second half of 2028.
  • GAAP R&D expense fell to $52.6 million from $68.6 million, while cost of license revenue was $9.0 million, tied to the VEPPANU approval and Rigel agreement.

The filing

CompanyARVINAS, INC. (ARVN)
Form8-K, current report
Filed with the SECAug 4, 2026, 7:02 AM ET
Accession number0001628280-26-052139

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.